New inhaler shows promise for COPD in early trial
NCT ID NCT07450482
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2a study tested an inhaled drug called JKN2304 in 42 adults with moderate-to-severe COPD. Participants received either JKN2304, a placebo, or an active comparator (formoterol) for 14 days. The main goal was to check safety, and researchers also measured changes in lung function. The trial is complete, but results are not yet publicly available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JKN2304 inhalation solution
- What this could lead to
- If successful, this could lead to a new inhaled treatment option for people with moderate-to-severe COPD to help improve lung function and ease breathing.
- What could go wrong
- This is an early Phase 2a trial with only 42 participants and a short 14-day treatment period. The results may not translate to long-term benefits or apply to all COPD patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangzhou First People's Hospital
Guangzhou, Guangdong, China
-
Huadong Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
-
Jiangyin Hospital of Traditional Chinese Medicine
Jiangyin, Jiangsu, China
-
Liuyang People's Hospital
Guankou, Hunan, China
-
Shanghai Pudong New Area People's Hospital
Shanghai, Shanghai Municipality, China
-
The Affiliated Hospital of Yangzhou University
Yangzhou, Jiangsu, China
-
Weifang Second People's Hospital
Weifang, Shandong, China
-
Zhangzhou Hospital, Fujian Province
Zhangzhou, Fujian, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital inhaler coach and breathing trainer put to the test against COPD attacks
- A handheld device that vibrates the airways may help COPD patients breathe easier
- Ancient breathing techniques put to the test for COPD relief
- Can scientists unlock the secrets of breathing muscle failure in severe COPD?
- Breathing battle: which technique helps COPD patients breathe easier?
- Common mucus-thinning drugs may improve outcomes in COPD patients with lung cancer